Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp decreased its position in Illumina, Inc. (NASDAQ:ILMN) by 23.7% in the 4th quarter, Holdings Channel reports. The institutional investor owned 35,500 shares of the life sciences company’s stock after selling 11,000 shares during the period. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp’s holdings in Illumina were worth $10,648,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of ILMN. Vanguard Group Inc grew its holdings in Illumina by 1.8% in the 3rd quarter. Vanguard Group Inc now owns 10,833,784 shares of the life sciences company’s stock worth $3,976,649,000 after acquiring an additional 188,516 shares during the last quarter. Oregon Public Employees Retirement Fund grew its holdings in Illumina by 66,581.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 10,562,335 shares of the life sciences company’s stock worth $35,000 after acquiring an additional 10,546,495 shares during the last quarter. Jennison Associates LLC grew its holdings in Illumina by 13.5% in the 4th quarter. Jennison Associates LLC now owns 5,479,564 shares of the life sciences company’s stock worth $1,643,486,000 after acquiring an additional 653,348 shares during the last quarter. Capital International Investors bought a new stake in Illumina in the 3rd quarter worth $1,482,837,000. Finally, Geode Capital Management LLC grew its holdings in Illumina by 10.1% in the 4th quarter. Geode Capital Management LLC now owns 1,854,346 shares of the life sciences company’s stock worth $555,173,000 after acquiring an additional 170,046 shares during the last quarter. Hedge funds and other institutional investors own 89.18% of the company’s stock.

In related news, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction dated Wednesday, December 26th. The shares were sold at an average price of $273.87, for a total transaction of $903,771.00. Following the sale, the director now owns 339,879 shares of the company’s stock, valued at $93,082,661.73. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Karin Eastham sold 5,000 shares of the business’s stock in a transaction dated Wednesday, January 2nd. The stock was sold at an average price of $294.08, for a total transaction of $1,470,400.00. Following the sale, the director now directly owns 12,655 shares in the company, valued at approximately $3,721,582.40. The disclosure for this sale can be found here. Insiders have sold 35,526 shares of company stock worth $10,501,041 in the last three months. 0.54% of the stock is currently owned by insiders.

Shares of ILMN opened at $315.30 on Thursday. The stock has a market cap of $45.67 billion, a PE ratio of 55.12, a P/E/G ratio of 2.21 and a beta of 1.18. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.27 and a current ratio of 2.49. Illumina, Inc. has a 1-year low of $225.82 and a 1-year high of $372.61.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, January 29th. The life sciences company reported $1.32 earnings per share for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). The company had revenue of $867.00 million for the quarter, compared to the consensus estimate of $865.33 million. Illumina had a net margin of 24.79% and a return on equity of 24.51%. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same period in the previous year, the firm posted $1.44 EPS. Research analysts expect that Illumina, Inc. will post 6.53 EPS for the current year.

A number of brokerages have issued reports on ILMN. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $339.00 price target on the stock in a report on Friday, February 22nd. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their price target for the stock from $340.00 to $370.00 in a report on Thursday, January 3rd. BidaskClub lowered shares of Illumina from a “hold” rating to a “sell” rating in a research note on Tuesday, January 29th. Leerink Swann raised shares of Illumina to an “outperform” rating and cut their target price for the company from $380.00 to $365.00 in a research note on Wednesday, January 30th. Finally, Bank of America reaffirmed a “buy” rating and set a $355.00 target price on shares of Illumina in a research note on Wednesday, January 30th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Illumina currently has an average rating of “Buy” and a consensus price target of $345.82.

ILLEGAL ACTIVITY WARNING: “Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp Has $10.65 Million Holdings in Illumina, Inc. (ILMN)” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2019/03/21/her-majesty-the-queen-in-right-of-the-province-of-alberta-as-represented-by-alberta-investment-management-corp-has-10-65-million-holdings-in-illumina-inc-ilmn.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

See Also: Leveraged Buyout (LBO)

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.